Key result
Point-of-care capillary PT test strongly correlates with lab NOAC levels at ~0.90.
Why the study?
There is a clinical need for point-of-care methods to measure non-vitamin K-dependent oral anticoagulants (NOACs).
Can a modified point-of-care prothrombin time method accurately measure the concentrations of non-vitamin K-dependent oral anticoagulants?
Can a modified point-of-care prothrombin time method accurately measure the concentrations of non-vitamin K-dependent oral anticoagulants?
Effect estimate: linear correlation coefficient 0.90
A modified point-of-care prothrombin time assay can accurately measure concentrations of dabigatran, apixaban, and rivaroxaban using a single reagent.
May enable decentralized NOAC monitoring; extends lab correlations to capillary samples but leaves clinical adoption open.
BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena's Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase or decrease NOAC interference, two assay variants were devised by replacing the standard 10 µL end-to-end capillary used to add the citrated plasma sample to 200 µL of prothrombin time (PT) reagent by either a 20 µL or a 5 µL capillary. All assay variants were calibrated to show correct PT results in plasma samples from healthy and warfarin-treated persons. RESULTS: For plasmas spiked with dabigatran, apixaban, or rivaroxaban, the 20 µL variant showed markedly higher PT results than the 5 µL. The effects were even more pronounced at room temperature than at +37 °C. In plasmas from patients treated with NOACs (n = 30 for each) there was a strong correlation between the PT results and the concentration of NOACs as determined by the central hospital laboratory. For the 20 µL variant the PT response of linear correlation coefficient averaged 0.90. The PT range was INR 1.1-2.1 for dabigatran and apixaban, and INR 1.1-5.0 for rivaroxaban. Using an INR ratio between the 20 µL and 5 µL variants (PTr20/5) made the NOAC assay more robust and independent of the patient sample INR value in the absence of NOAC. Detection limits were 80 µg/L for apixaban, 60 µg/L for dabigatran, and 20 µg/L for rivaroxaban. CONCLUSIONS: A wet-chemistry POC PT procedure was modified to measure the concentrations of three NOACs using a single reagent.
No takes yet. Share an insight, caveat, or question.
Lindahl et al. (2017) studied Patients treated with NOACs (n=90). Modified Zafena Simple Simon PT-INR (20 µL capillary variant) vs. Central hospital laboratory NOAC concentration was evaluated on Correlation between PT results and NOAC concentration (linear correlation coefficient 0.90). A modified wet-chemistry point-of-care prothrombin time procedure using a 20 µL capillary strongly correlated with central laboratory NOAC concentrations (average r=0.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: